靶向治疗改变了妇科癌症的治疗格局。去年发布的研究已将免疫疗法 (IO) 纳入所有子宫内膜癌和宫颈癌患者病程某个阶段的治疗中。聚（ADP-核糖）聚合酶（PARP）抑制剂继续在患有卵巢癌的女性中发挥作用，特别是在同源修复缺陷的肿瘤中。此外，PARP 抑制剂在具有挑战性的亚组中的益处仍在不断得到阐明。生物标志物鉴定已导致多种抗体药物偶联物 (ADC) 获得批准或列入目录。本综述将更新 IO、ADC 和 PARP 抑制治疗妇科癌症的最新进展。

Targeted therapies have changed the treatment landscape in gynecologic cancer. Studies released over the past year have led to the incorporation of immunotherapy (IO) into the treatment for all patients with endometrial and cervical cancers at some point during their disease course. Poly(ADP-ribose) polymerase (PARP) inhibitors continue to play a role in women with ovarian carcinoma, particularly in homologous repair deficient tumors. Furthermore, the benefit of PARP inhibitors in challenging subgroups continues to be elucidated. Biomarker identification has led to the approval or compendium listing of several antibody-drug conjugates (ADCs). This review will update on IO, ADCs, and PARP inhibition for the treatment of gynecologic cancers.